171
Views
1
CrossRef citations to date
0
Altmetric
Original Research

Characteristics, Risk Factors, and Prevalence of Clostridioides difficile Among Hospitalized Patients in a Tertiary Care Hospital in Palestine

, , , ORCID Icon, , & show all
Pages 4681-4688 | Published online: 09 Nov 2021

References

  • Czepiel J, Dróżdż M, Pituch H, et al. Clostridium difficile infection: review. Eur J Clin Microbiol Infect Dis. 2019;38(7):1211–1221. doi:10.1007/s10096-019-03539-630945014
  • Balsells E, Shi T, Leese C, et al. Global burden of Clostridium difficile infections: a systematic review and meta-analysis. J Glob Health. 2019;9:1.
  • Marley C, El Hahi Y, Ferreira G, Woods L, Ramirez Villaescusa A. Evaluation of a risk score to predict future Clostridium difficile disease using UK primary care and hospital data in clinical practice research datalink. Hum Vaccin Immunother. 2019;15(10):2475–2481. doi:10.1080/21645515.2019.158928830945972
  • McDonald LC, Gerding DN, Johnson S, et al. Clinical practice guidelines for Clostridium difficile infection in adults and children: 2017 update by the Infectious Diseases Society of America (IDSA) and Society for Healthcare Epidemiology of America (SHEA). Clin Infect Dis. 2018;66(7):e1–e48.29462280
  • Thabit AK, Varugehese CA, Levine AR. Antibiotic use and duration in association with Clostridioides difficile infection in a tertiary academic medical center: a retrospective case-control study. Anaerobe. 2019;59:126–130. doi:10.1016/j.anaerobe.2019.06.01631254655
  • Webb BJ, Subramanian A, Lopansri B, et al. Antibiotic exposure and risk for hospital-associated Clostridioides difficile infection. Antimicrob Agents Chemother. 2020;64(4):e02169–e02219. doi:10.1128/AAC.02169-1931964789
  • Eze P, Balsells E, Kyaw MH, Nair H. Risk factors for Clostridium difficile infections - an overview of the evidence base and challenges in data synthesis. J Glob Health. 2017;7(1):010417. doi:10.7189/jogh.07.01041728607673
  • Cui Y, Dong D, Zhang L, et al. Risk factors for Clostridioides difficile infection and colonization among patients admitted to an intensive care unit in Shanghai, China. BMC Infect Dis. 2019;19(1):1. doi:10.1186/s12879-019-4603-130606108
  • Natarajan M, Rogers MA, Bundy J, et al. Gender differences in non-toxigenic Clostridium difficile colonization and risk of subsequent C. difficile infection. Clin Res Infect Dis. 2015;2:2.
  • Asempa T, Nicolau D. Clostridium difficile infection in the elderly: an update on management. Clin Interv Aging. 2017;12:1799–1809. doi:10.2147/CIA.S14908929123385
  • Jump RL. Clostridium difficile infection in older adults. Aging Health. 2013;9(4):403–414. doi:10.2217/ahe.13.3724955106
  • Miranda-Katz M, Parmar D, Dang R, Alabaster A, Greenhow TL. Epidemiology and risk factors for community associated Clostridioides difficile in children. J Pediatr. 2020;221:99–106. doi:10.1016/j.jpeds.2020.02.00532171559
  • Tschudin-Sutter S, Tamma PD, Naegeli AN, Speck KA, Milstone AM, Perl TM. Distinguishing community-associated from hospital-associated Clostridium difficile infections in children: implications for public health surveillance. Clin Infect Dis. 2013;57(12):1665–1672. doi:10.1093/cid/cit58124046303
  • Olsen MA, Stwalley D, Demont C, Dubberke ER. Increasing age has limited impact on risk of Clostridium difficile infection in an elderly population. Open Forum Infect Dis. 2018;5(7):7. doi:10.1093/ofid/ofy160
  • Kamboj M, Gennarelli R, Brite J, Sepkowitz K, Lipitz-Snyderman A. Risk for Clostridioides difficile infection among older adults with cancer. Emerg Infect Dis J. 2019;25(9):1683. doi:10.3201/eid2509.181142
  • Revolinski SL, Munoz-Price LS. Clostridium difficile in immunocompromised hosts: a review of epidemiology, risk factors, treatment, and prevention. Clin Infect Dis. 2019;68(12):2144–2153. doi:10.1093/cid/ciy84530281082
  • Solomon K. The host immune response to Clostridium difficile infection. Ther Adv Infect Dis. 2013;1(1):19–35. doi:10.1177/204993611247217325165542
  • Taking antibiotics increases your risk for C. diff infection. Center For Disease Control And Prevention; 2021. Available from: https://www.cdc.gov/cdiff/risk.html. Accessed June 15, 2021.
  • Teng C, Reveles KR, Obodozie-Ofoegbu OO, Frei CR. Clostridium difficile infection risk with important antibiotic classes: an analysis of the FDA adverse event reporting system. Int J Med Sci. 2019;16(5):630–635. doi:10.7150/ijms.3073931217729
  • Choucair J, Waked R, Haddad E, et al. Clostridioides difficile infections: epidemiology, correlations and treatment in a Lebanese cohort with use of ATLAS scoring. J Infect Dev Ctries. 2020;14(12):1461–1465. doi:10.3855/jidc.1318933378291
  • Alammari KM, Thabit AK. Characteristics of patients infected with Clostridioides difficile at a Saudi Tertiary Academic Medical Center and assessment of antibiotic duration. Gut Pathog. 2021;13(1):10. doi:10.1186/s13099-021-00405-933593421
  • Elgendy SG, Aly SA, Fathy R, Deaf EAE, Abu Faddan NH, Abdel Hameed MR. Clinical and microbial characterization of toxigenic Clostridium difficile isolated from antibiotic associated diarrhea in Egypt. Iran J Microbiol. 2020;12(4):296–304.32994900
  • Castro I, Tasias M, Calabuig E, Salavert M. Doctor, my patient has CDI and should continue to receive antibiotics. The (unresolved) risk of recurrent CDI. Rev Esp Quimioter. 2019;32(Suppl 2):47–54.31475811
  • NICE. Clostridium difficile infection: risk with broad-spectrum antibiotics; 2021. Available from: https://www.nice.org.uk/advice/esmpb1/chapter/Key-points-from-the-evidence. Accessed November 1, 2021.
  • Bingley PJ, Harding GM. Clostridium difficile colitis following treatment with metronidazole and vancomycin. Postgrad Med J. 1987;63(745):993–994. doi:10.1136/pgmj.63.745.9933451227
  • Hecht JR, Olinger EJ. Clostridium difficile colitis secondary to intravenous vancomycin. Dig Dis Sci. 1989;34(1):148–149. doi:10.1007/BF15361722910675
  • Leonard J, Marshall JK, Moayyedi P. Systematic review of the risk of enteric infection in patients taking acid suppression. Am J Gastroenterol. 2007;102(9):2047–2056. doi:10.1111/j.1572-0241.2007.01275.x17509031
  • Patil R, Blankenship L. Proton pump inhibitors and clostridium difficile infection: are we propagating an already rapidly growing healthcare problem? Gastroenterol Res. 2013;6(5):171. doi:10.4021/gr575w
  • Gouraud A, Vochelle V, Descotes J, Vial T. Proton pump inhibitor-induced neutropenia. Clin Drug Investig. 2010;30(8):559–563. doi:10.2165/11537230-000000000-00000
  • Leontiadis GI, Miller MA, Howden CW. How much do PPIs contribute to C. difficile infections? Am J Gastroenterol. 2012;107(7):1020–1021. doi:10.1038/ajg.2012.17422764024
  • Azab M, Doo L, Doo DH, et al. Comparison of the hospital-acquired Clostridium difficile Infection risk of using proton pump inhibitors versus histamine-2 receptor antagonists for prophylaxis and treatment of stress ulcers: a systematic review and meta-analysis. Gut Liver. 2017;11(6):781–788. doi:10.5009/gnl1656828506028
  • Haider F, Raza N, Komar M, Rahman O, Sartorius J, Kirchner H. Proton pump inhibitor use elevates the risk of severe Clostridium difficile colitis. J Gastroenterol Hepatol Res. 2012;1(4):53–56.
  • Lewis PO, Litchfield JM, Tharp JL, Garcia RM, Pourmorteza M, Reddy CM. Risk and severity of hospital-acquired Clostridium difficile infection in patients taking proton pump inhibitors. Pharmacotherapy. 2016;36(9):986–993. doi:10.1002/phar.180127455386
  • Juneau C, Mendias EP, Wagal N, et al. Community-acquired Clostridium difficile infection: awareness and clinical implications. J Nurse Pract. 2013;9(1):1–6. doi:10.1016/j.nurpra.2012.10.00723814528
  • Oake N, Taljaard M, Van Walraven C, Wilson K, Roth V, Forster AJ. The effect of hospital-acquired clostridium difficile infection on in-hospital mortality. Arch Intern Med. 2010;170(20):1804–1810. doi:10.1001/archinternmed.2010.40521059973
  • Zumla A. Mandell, Douglas, and Bennett’s principles and practice of infectious diseases. Lancet Infect Dis. 2010;10(5):303–304. doi:10.1016/S1473-3099(10)70089-X
  • Wilkins TD, Lyerly DM. Clostridium difficile testing: after 20 years, still challenging. J Clin Microbiol. 2003;41(2):531–534. doi:10.1128/JCM.41.2.531-534.200312574241
  • Voth DE, Ballard JD. Clostridium difficile toxins: mechanism of action and role in disease. Clin Microbiol Rev. 2005;18(2):247–263. doi:10.1128/CMR.18.2.247-263.200515831824